Post-transcriptional Regulation of BRCA2 Through Interactions with MiR-19a and MiR-19b
Overview
Authors
Affiliations
Breast cancer type 2, early onset susceptibility gene (BRCA2) is a major component of the homologous recombination DNA repair pathway. It acts as a tumor suppressor whose function is often lost in cancers. Patients with specific mutations in the BRCA2 gene often display discrete clinical, histopathological, and molecular features. However, a subset of sporadic cancers has wild type BRCA2 and display defects in the homology-directed repair pathway, which is the hallmark of 'BRCAness.' The mechanisms by which BRCAness arises are not well understood but post-transcriptional regulation of BRCA2 gene expression by microRNAs (miRNAs) may contribute to this phenotype. Here, we examine the post-transcriptional effects that some members of the six-miRNA cluster known as the miR-17/92 cluster have on the abundance of BRCA2's messenger RNA (mRNA) and protein. We discuss two interactions involving the miR-19a and miR-19b members of the cluster and the 3'UTR of BRCA2's mRNA. We investigated these miRNA:mRNA interactions in 15 cell lines derived from pancreatic, breast, colon, and kidney tissue. We show that over-expression of these two miRNAs results in a concomitant decrease of BRCA2's mRNA and protein expression in a subset of the tested cell lines. Additionally, using luciferase reporter assays we identified direct interactions between miR-19a/miR-19b and a miRNA response element (MRE) in BRCA2's 3'UTR. Our results suggest that BRCA2 is subject to a complex post-transcriptional regulatory program that has specific dependencies on the genetic and phenotypic background of cell types.
An integrated analysis of microRNAs regulating DNA damage response in triple-negative breast cancer.
Kuthethur R, Jerome M, Subbannayya Y, Chakrabarty S Breast Cancer. 2023; 30(5):832-844.
PMID: 37344703 PMC: 10404216. DOI: 10.1007/s12282-023-01477-y.
The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis.
Lin K, Baritaki S, Vivarelli S, Falzone L, Scalisi A, Libra M Antioxidants (Basel). 2022; 11(6).
PMID: 35740092 PMC: 9227079. DOI: 10.3390/antiox11061195.
Darbeheshti F, Kadkhoda S, Keshavarz-Fathi M, Razi S, Bahramy A, Mansoori Y BMC Cancer. 2022; 22(1):668.
PMID: 35715772 PMC: 9206264. DOI: 10.1186/s12885-022-09761-4.
Chen Q, Wu C, Yao Z, Cai L, Ni Y, Mao S Anim Nutr. 2021; 7(4):1315-1328.
PMID: 34786504 PMC: 8567331. DOI: 10.1016/j.aninu.2021.10.002.
De Marchi T, Pyl P, Sjostrom M, Klasson S, Sartor H, Tran L J Proteome Res. 2021; 20(5):2983-3001.
PMID: 33855848 PMC: 8155562. DOI: 10.1021/acs.jproteome.1c00243.